Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Phase 4
Completed
- Conditions
- Breast CancerMultiple MyelomaProstate Cancer
- Registration Number
- NCT00029224
- Lead Sponsor
- Novartis
- Brief Summary
Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Pain score assessed by change from baseline
- Secondary Outcome Measures
Name Time Method Quality of life Time in infusion chair Safety assessed by adverse events (AEs)
Trial Locations
- Locations (7)
Osceola Cancer Center
๐บ๐ธKissimmee, Florida, United States
Stockton Hematology Oncology Medical Group
๐บ๐ธStockton, California, United States
Hematology-Oncology Associates PC
๐บ๐ธAlbuquerque, New Mexico, United States
New Mexico Oncology Hematology Consultants
๐บ๐ธAlbuquerque, New Mexico, United States
Virginia Physicians, Inc
๐บ๐ธRichmond, Virginia, United States
Hematology Oncology Associates, PC
๐บ๐ธMedforo, Oregon, United States
Nevada Cancer Center
๐บ๐ธLas Vegas, Nevada, United States